Volitionrx (VNRX) Non-Current Deffered Revenue (2024 - 2025)
Volitionrx posted quarterly Non-Current Deffered Revenue of $21.9 million for Q4 2025, down 3.2% year-on-year from $22.7 million in Q4 2024, and little changed on a QoQ basis from $22.0 million in Q3 2025.
Volitionrx (VNRX) has 2 years of Non-Current Deffered Revenue data on file, last reported at $21.9 million in Q4 2025.
- For the quarter ending Q4 2025, Non-Current Deffered Revenue fell 3.2% year-over-year to $21.9 million; the trailing twelve-month figure through Dec 2025 stood at $21.9 million (down 3.2% YoY), and the FY2025 full-year result was $21.9 million, down 3.2% from the prior year.
- Non-Current Deffered Revenue for Q4 2025 stood at $21.9 million, roughly flat from $22.0 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $22.7 million in Q4 2024 and bottomed at $21.9 million in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | - |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | - |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | - |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | - |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 512.79 Mn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | - |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | - |
| 10 | Volitionrx | 101.83 Mn | 99.36 Mn | -1.01 Mn | 21.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 21.94 Mn |
| Sep 30, 2025 | 22.03 Mn |
| Jun 30, 2025 | 22.66 Mn |
| Mar 31, 2025 | 22.66 Mn |
| Dec 31, 2024 | 22.66 Mn |